Signals
China Just Put a Bispecific ADC Into Esophageal Cancer
China’s NMPA approved iza-bren for recurrent or metastatic esophageal squamous cell carcinoma after platinum chemotherapy and PD-1/PD-L1 therapy. The approval is a regulatory win, but the bigger story is China’s growing ability to move ADC innovation into high-burden cancers.
When Dementia Takes Speech, Trials Must Catch Up
Child Mental Health Access Still Depends on the Facility
Europe Built Seasonal COVID Campaigns. Most Older Adults Were Not Reached.
Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge
Ultra-processed food may leave a metabolic fingerprint in the blood.
Huntington’s Gets Another Chance at Proof
New global heart failure definition exposes a policy gap: systems still diagnose too late and treat too narrowly
Sugar substitutes were sold as metabolic shortcuts. The evidence is getting harder to ignore
Early Lung Cancer Just Became a Biomarker Test of the System
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.